THE CURRENT TRENDS OF PSORIASIS TREATMENT IN DERMATOLOGICAL PRACTICE

Mutaia Abuarij; Ali Alyahawi; Ali Alkaf

doi:10.22270/ujpr.v9i5.1200

Mutaia Abuarij Faculty of Medicine, Dermatology Department, 21 September University for Medical & Applied Sciences, Yemen.
Ali Alyahawi Faculty of Clinical Pharmacy, 21 September University for Medical and Applied Sciences, Yemen.
Ali Alkaf Faculty of Pharmacy, Sanaa University, Yemen.

10.22270/ujpr.v9i5.1200

Keywords:

Biologic agents, combination therapies, guidelines for psoriasis, topical corticosteroids

Abstract

Psoriasis is associated with many complications. The severity of the disease can range from mild or moderate to severe. Treatment for this condition should be long-term and multifaceted, and may change over time based on the condition severity. Treatment for patients with psoriasis often includes treatment of the underlying pathophysiology. Other treatments for psoriasis include topical medications, phototherapy, and medications (nonspecific/biologic and biologic). Pharmacologic therapy is generally guided by disease severity and impact on patient quality of life, ranging from topical medications to phototherapy and, when necessary, systemic medications. However, challenges remain, including side effects, poor treatment, high costs, and variability in individual responses. Recent biologics have proven effective in psoriasis; on the other hand, there are differences among these drugs such as mechanisms of action, duration of response, and side effects. Biologics are often used to treat moderate to severe psoriasis and can be the treatment of choice, particularly in patients with comorbidities such as psoriatic arthritis or in whom psoriasis treatments such as methotrexate or cyclosporine are contraindicated. Different types of therapy are often used in combination. Combined therapies may improve treatment. Clinical guidelines classify psoriasis as mild or mild to severe, with mild lesions managed locally and moderate to severe lesions managed systemically.